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Lung squamous cell carcinoma (LSCC) and adenocarcinoma (LADC) are the most common lung cancer subtypes. Molecular 
targeted treatments have improved LADC patient survival but are largely ineffective in LSCC. The tumor suppressor FBW7 
is commonly mutated or down-regulated in human LSCC, and oncogenic KRasG12D activation combined with Fbxw7 
inactivation in mice (KF model) caused both LSCC and LADC. Lineage-tracing experiments showed that CC10+, but not basal, 
cells are the cells of origin of LSCC in KF mice. KF LSCC tumors recapitulated human LSCC resistance to cisplatin-based 
chemotherapy, and we identified LUB AC-mediated NF-κB signaling as a determinant of chemotherapy resistance in human 
and mouse. Inhibition of NF-κB activation using TAK1 or LUB AC inhibitors resensitized LSCC tumors to cisplatin, suggesting a 
future avenue for LSCC patient treatment.
LUB AC determines chemotherapy resistance in 
squamous cell lung cancer
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Introduction
Lung cancer is the most common epithelial tumor and the 
leading cause of cancer death worldwide. It is histologically 
differentiated into small cell lung cancer (SCLC) and non–
small cell lung cancer (NSC LC). NSC LC tumors can be further 
subdivided into lung adenocarcinoma (LADC), squamous cell 
carcinoma (LSCC), and the rarer large cell carcinoma. Progress 
has been made in the targeted treatment of LADC, largely due to 
the development of small-molecule inhibitors against epidermal 
growth factor receptor (EGFR), anaplastic lymphoma receptor 
tyrosine kinase (ALK), and ROS1 (Cardarella and Johnson, 2013). 
However, such treatments have proved ineffective for LSCC 
patients (Novello et al., 2014; Hirsch et al., 2017). This, together 
with the lack of LSCC-specific therapeutic targets, has resulted in 
few recent significant advances in the treatment of this disease 
(Liao et al., 2012; Gandara et al., 2015). Consequently, despite 
its limited effectiveness on disease progression and prognosis, 
platinum-based chemotherapy remains the cornerstone of 
current treatment for LSCC (Scagliotti et al., 2008; Fennell et 
al., 2016; Isaka et al., 2017). Therefore, elucidating the critical 
molecular pathways involved in LSCC is crucial to identify new 
therapeutic approaches.
Comprehensive genetic analyses of human LSCC samples re-
vealed numerous genomic alterations in genes such as PIK3CA, 
TP53, CDKN2A, and FBXW7 (Kan et al., 2010; Cancer Genome 
Atlas Research Network, 2012). The FBXW7 protein product 
F-box/WD repeat-containing protein 7 (FBW7) is the substrate 
recognition component of a Skp, Cullin, F-box–type ubiquitin li-
gase, which targets several well-known oncoproteins, including 
c-Myc, Notch, and c-Jun, for degradation (Davis et al., 2014).
The NF-κB pathway is involved in multiple steps in tumori-
genesis and chemoresistance (Zhang et al., 2017). In physiological 
conditions, this pathway is tightly regulated by ubiquitylation. 
Ubiquitin (Ub) chains regulate the degradation of the IκB pro-
teins and also serve as a scaffolding, recruitment, and activation 
platform in receptor signaling complexes. Lysine-63 (K63)– and 
methionine-1 (M1)–linked ubiquitin chains mediate the key up-
stream events of recruiting TAK1 and the IKK complex, respec-
tively, resulting in the activation of the NF-κB pathway (Jiang 
and Chen, 2011; Emmerich et al., 2013). The linear Ub chain as-
sembly complex (LUB AC) specifically assembles M1-linked Ub 
chains on the IKK complex subunit NEMO/IKKγ. Recent findings 
suggest a role of LUB AC in tumor formation in which excessive 
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LUB AC activation causes abnormal NF-κB signaling and tumor 
growth (Yang et al., 2014) and attenuates chemotoxicity in cell 
lines (MacKay et al., 2014). Although NF-κB activation has been 
reported in several tumors including lung cancer (Karin and 
Greten, 2005), the potential role of the LUB AC–NF-κB pathway 
in LSCC tumors is unknown.
Here, we describe a novel genetic mouse model in which the 
loss of Fbxw7 concomitant with KRasG12D activation (KF mice) 
promoted the formation of two NSC LC cancers, LSCC as well as 
LADC. LADC and LSCC were found in distinct anatomical loca-
tions, as observed in humans. Whereas LADC exclusively formed 
in the alveolar space, LSCC was found near the airways. Club 
CC10+ cells, but not basal cytokeratin 5–positive (CK5+) cells, 
were the cells of origin of LSCC in the KF model. Moreover, we 
found that LSCC tumors were resistant to cisplatin chemother-
apy and identified the LUB AC complex as a determinant of che-
motherapy resistance. Inhibition of LUB AC or NF-κB signaling 
resulted in sensitization of LSCC tumors to cisplatin, suggesting 
a future avenue for LSCC patient treatment.
Results
FBW7 is frequently lost in human LSCC
Genomic studies of human LSCC have reported recurrent mu-
tations in the FBXW7 tumor suppressor gene (Kan et al., 2010; 
Campbell et al., 2016). Data from The Cancer Genome Atlas (TCGA) 
show 6.4% of human LSCC cases with mutations in FBXW7, the 
majority associated with loss of function (Fig. S1 A; Cerami et 
al., 2012). Moreover, immunohistochemistry (IHC) staining on 
human lung biopsy samples showed that only 31% (11/35) of LSCC 
tumor samples expressed detectable levels of FBW7 protein. In 
contrast, 85% (22/26) of human LADC samples were positive for 
FBW7 staining, and adjacent normal lung tissue was positive for 
FBW7 in all patients (Fig. 1, A and B). These data suggest that FBW7 
is lost or down-regulated frequently in human LSCC, and hence 
that FBW7 inactivation could be a driver of human LSCC.
Fbxw7 inactivation, together with oncogenic KRas activation, 
results in LSCC as well as LADC tumors in the mouse lung
Conditional activation of oncogenic KRasG12D in the mouse lung is 
a well-established mouse model of human LADC (Jackson et al., 
2001). KRAS mutations are very frequently observed in human 
LADC, but the RAS tumor driver pathway is also activated in up 
to half of human LSCC tumors, most commonly due to transcrip-
tional up-regulation and amplification of KRAS and the upstream 
receptor tyrosine kinases EGFR and FGFR1 (Fig. S1 A; Cancer 
Genome Atlas Research Network, 2012; Campbell et al., 2016).
Intratracheal administration of Cre-expressing adenovirus 
in LSL-KRasG12D mice results in the formation of LADC (DuPage 
et al., 2009). To investigate whether genetic loss of Fbxw7 con-
comitant with oncogenic KRasG12D activation would alter the lung 
tumor type produced in this model, we generated a conditional 
LSL-KRasG12D; Fbxw7f/f (KF) mouse strain. Animals were admin-
istered with adenovirus expressing Cre recombinase under the 
control of the ubiquitous CMV promoter (Ad5-CMV-Cre) via in-
tratracheal intubation, and the lungs were analyzed 9–12 wk after 
virus administration (Fig. 1 C).
Control LSL-KRasG12D mice developed only LADC, as previ-
ously reported (Jackson et al., 2001; Fig. S1 B). However, 100% 
of KF mice developed two distinct types of NSC LC upon Cre-me-
diated recombination: a tumor type that resembled LADC, and a 
second lung cancer subtype resembling LSCC (Fig. 1 D). The ratio 
of LSCC to LADC lung tumors formed in the KF mouse model was 
on average 1:1 (Fig. 1 E).
The two tumor types were blindly analyzed and classified by 
a clinical pathologist as LADC and LSCC according to the most 
recent World Health Organization criteria (Travis et al., 2015). 
Both tumor types resembled their human counterparts histo-
logically (Fig. 1 F). LADC occurred exclusively in alveolar lung 
tissue and displayed solid, acinar, lepidic, and papillary growth 
patterns. Moreover, LADC cells were positive for TTF1 and nega-
tive for CK5 and ΔNp63 staining (Fig. 1 F). LSCC occurred mainly 
in bronchi (occasionally manifesting as small foci in alveolar lung 
tissue), showed largely solid growth patterns, with occasional 
intracellular bridges and rare keratinization, and were negative 
for TTF1 but expressed CK5 and ΔNp63 (Fig. 1 F). We observed 
infiltration of neutrophils, but not macrophages, CD4+, or CD8+ 
T cells. As has been described for the Lkb1f/f, Ptenf/f LSCC model, 
the immune evasion markers PD-1 and PD-L1 were expressed in 
KF LSCC tumors, and they were positive for NGFR and Sox2, two 
other markers shown to be characteristic of human and mouse 
LSCC (Fig. S1 C; Xu et al., 2014).
To further characterize the tumor types arising in the KF 
model, we isolated LADC and LSCC cells from KF lungs and per-
formed transcriptome analysis (RNASeq). LSCC cells displayed 
a strong LSCC gene signature, selected from published gene sets 
up-regulated in Lkb1f/f, Ptenf/f LSCC (Xu et al., 2014), LSL-Sox2; 
Ptenf/f; Cdkn2abf/f LSCC, and human LSCC (Ferone et al., 2016; 
Fig. 1 G). LADC cells from the same animals did not express this 
gene signature, underlining that distinct tumor types arise from 
the same oncogene combination in the KF model (Fig. 1 G). One 
possibility that could explain this duality is that LSCC and LADC 
tumors arise from different cells of origin. We therefore investi-
gated the cell of origin of LSCC in the KF model.
Basal cells do not give rise to LSCC in the KF model
Different cell types have been reported to give rise to LSCC 
(Ferone et al., 2016). Basal cells are considered potential cells of 
origin of LSCC, as they share certain markers with LSCC tumor 
cells, including cytokeratin 5 expression. KF animals were there-
fore crossed with two Cre lines driving recombination in basal 
cells, using cytokeratin 5 or cytokeratin 14 promoters (CK5-
CreERT or CK14-CreERT mice; Indra et al., 1999; Vasioukhin et al., 
1999). Both CK5-CreERT; KF and CK14-CreERT; KF mice developed 
skin and life-limiting oral tumors after 3–4 wk. At that time no 
lung tumors were detectable (data not shown), so the analysis of 
lung tumorigenesis at later stages was precluded.
To be able to analyze LSCC development at later time points, 
we generated recombinant viruses expressing Cre recombinase 
driven by the cytokeratin 5 promoter (Ramirez et al., 2004). To 
validate the specificity of Ad5-CK5-Cre virus, Rosa-CAG-LSL-
tdTomato lineage tracer mice were treated with naphthalene 
to deplete Club secretory cells and to expose the basal cell layer, 
and high-titer recombinant viruses were then administered 
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Figure 1. Biallelic inactivation of Fbxw7 and KRasG12D activation in the adult mouse lung leads to LSCC and LADC formation. (A) Representative human 
lung LADC (i–iv) and LSCC (v–viii) tumors and control lung sections stained with FBW7 antibodies. Bars, 20 µm. (B) Quantification of FBW7 protein staining 
in human LADC and LSCC tumors as in A. n = 26 LADC, 35 LSCC. (C) Biallelic inactivation of Fbxw7 and KRasG12D activation by intratracheal (IT) delivery of 
Ad5-CMV-Cre virus in the adult mouse lung as a model of NSC LC. (D) KF model develops LSCC (CK5+) and LADC (TTF1+) tumors. Sections representative of 
six animals. (E) Quantification and localization of mouse lung LADC and LSCC tumors in the KF model. n = 15 lungs. Plots indicate mean ± SD. (F) Human and 
mouse NSC LC samples were stained with biomarkers used clinically to distinguish LADC (TTF1) from LSCC (CK5 and ΔNp63) tumors. Bars, 100 µm (columns 
1 and 4); 20 µm (columns 2 and 5). Sections representative of six animals. (G) Heat map of RNASeq data showing relative expression of LSCC genes in LADC 
and LSCC tumors from n = 3 mice of the KF genotype. Gene set shown is selected from gene sets up-regulated in Lkb1f/f; Ptenf/f LSCC (Xu et al., 2014) and in 
LSL-Sox2; Ptenf/f; Cdkn2abf/f LSCC and human LSCC (Ferone et al., 2016). Genes are ordered according to z-score. See also Fig. S1.
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intratracheally. Targeted cells were identified by IHC staining 
for RFP/Tomato and cellular location. At 3 and 12 wk following 
Ad5-CK5-Cre infection, traced cells were found lining the basal 
layer of tracheal sections and showed CK5-positivity (Fig. S1 
D), validating the basal cell targeting of the virus. However, KF 
animals treated with naphthalene and Ad5-CK5-Cre did not 
develop lung tumors even after a long latency (30 wk; Fig. S1 
E). Thus, targeting Fbxw7Δ/Δ and KRasG12D specifically to CK5-
expressing cells failed to give rise to LSCC.
CK19+ luminal cells give rise to LSCC in the KF model
Because basal cells appear not to be the cell of origin of KF LSCC, 
we next tested whether luminal epithelial cells function as cells 
of origin in the KF lung cancer model. KF mice harboring the 
R26-LSL-YFP lineage tracer were crossed to CK19-CreERT mice to 
target the oncogenes to CK19-expressing cells in the adult lung, 
including club, ciliated, and alveolar cells (Iyonaga et al., 1997; 
Cole et al., 2010).
CK19-CreERT; KF; R26-LSL-YFP (CKFY) mice developed both 
LSCC and LADC tumors in an ∼1:1 ratio (Fig. S2 A). The histo-
pathology of both tumors in CKFY mice was identical to that 
observed following Ad5-CMV-Cre infection. LSCC tumors were 
located in and adjacent to the airways and expressed CK5 and 
ΔNp63, whereas LADCs were located in the alveoli and positive 
for TTF1 and Sftpc (Fig. S2 A). These data suggest that KF LSCC 
may initiate in luminal CK19+ cells that subsequently change 
their marker expression to give rise to the squamous phenotype.
CC10+ luminal cells initiate LSCC in the KF model
To identify the CK19+ luminal cell initiating LSCC tumors, we per-
formed lineage tracing in the CK19-CreERT; R26-LSL-YFP mouse 
model. Lineage-labeled CK19 cells in the airways were positive 
for the club cell marker CC10 or the ciliated cell markers FoxJ1 
and acetylated tubulin (AcTub) and negative for the goblet cell 
marker mucin 5Ac (Muc5Ac; Fig. 2 A and Fig. S2 B). Expression 
of FoxJ1 and CC10 did not overlap, enabling ciliated and club cells 
to be distinguished in the airways (Fig. S2 C). In the alveoli, CK19-
traced cells were positive for Sftpc, a marker of alveolar type II 
cells (Fig. 2 A; Barkauskas et al., 2013).
To target these cell types individually, we used recombinant 
viruses expressing Cre recombinase under the control of the FoxJ1 
promoter (Lenti-FoxJ1-Cre), the CC10 promoter (Ad5-CC10-Cre), 
or the Sftpc promoter (Ad5-Sftpc-Cre) to initiate tumorigenesis 
in ciliated, club, and alveolar type II cells, respectively (Zhang et 
al., 2007; Sutherland et al., 2011).
KF mice infected intratracheally with Lenti-FoxJ1-Cre virus 
did not develop LSCC tumors even after a long latency (30 wk; 
Fig. 2 B). Ciliated FoxJ1+ cells were able to give rise to very few 
lung tumors (average 0.3 per lung) located in and adjacent to the 
airways, but these were positive for TTF1 and Sftpc, not CK5 or 
ΔNp63, suggestive of LADC (Fig. 2 B and Fig. S3 A).
In contrast, KF mice infected with Ad5-CC10-Cre virus de-
veloped tumor lesions with histological characteristics of LSCC 
and were mainly located in and adjacent to the airways. Markers 
characteristic of human LSCC, CK5 and ΔNp63, were detected 
in these tumors (Fig. 2 C and Fig. S3 B). LSCC tumors were also 
observed in the alveoli, although at low frequency (Fig.  2  C). 
Ad5-CC10-Cre infection also resulted in LADC tumors, which 
were found exclusively in the alveolar space and displayed high 
expression of TTF1 and Sftpc as expected (Fig. 2 C and Fig. S3 
B). CC10+ cells originated predominantly LSCC (80%), with the 
remainder of the lesions being LADC tumors (Fig. 2 C).
It has recently been reported that alveolar type II cells also 
have the ability to form LSCC (Ferone et al., 2016). However, 
targeting alveolar type II cells with Ad5-Sftpc-Cre in KF mice 
resulted exclusively in TTF1- and Sftpc-expressing adenomas 
and adenocarcinomas distributed in the alveolar area (Fig. S3 C). 
Thus, whereas LADC tumors in the KF mouse model originate 
from Sftpc+ alveolar cells, LSCC tumors initiate in CC10+ luminal 
cells of the airways.
To analyze the progression of early LSCC lesions in the 
airways, we performed lineage tracing in the CKFY mouse 
model in combination with ethynyl deoxyuridine (EdU) staining 
to track the proliferation of targeted cells (Fig.  2  D). To trace 
only a small number of cells, we used a low dose of tamoxifen 
to induce recombination. Lung sections were costained for EdU 
and CC10 or CK5 to monitor tumor initiation. 16% of traced club 
(GFP+CC10+) cells proliferated as early as 3 d after tamoxifen 
injection, as indicated by EdU incorporation (Fig.  2, E and F; 
and Fig. S3 D). At 7 d, we observed a thickening of the airway 
epithelium, and CC10+ cells continued to proliferate strongly, 
with a third of traced CC10+ cells incorporating EdU. We began 
to observe lineage-traced CK5+ cells in the airways only around 
day 14 after recombination, and their numbers subsequently 
increased, accompanied by a decrease in CC10+ proliferating cells 
(Fig. 2, E and F; and Fig. S3 D). At 28 d after tamoxifen injection, 
we found traced lesions resembling LSCC in the airways, which 
were CK5+ and negative for CC10 (Fig. 2, E and F; and Fig. S3 D). 
These data support the notion that LSCC initiates in luminal 
CK19+ CC10+ cells that subsequently transdifferentiate to give 
rise to the squamous phenotype.
Primary KF LADC and LSCC tumor cells retain their identity and 
tumorigenic capacity in vitro
Human LADC and LSCC tumors differ not only in their 
localization and marker expression, but also in their response 
to therapy. LSCC patients receiving standard platinum-based 
first-line chemotherapy have shown lower overall survival than 
LADC patients (Scagliotti et al., 2008; Pirker et al., 2012). The 
development of two different tumor types in the same genetic 
model allows a side-by-side comparison of their characteristics 
without any confounding effects of different driver mutations. 
With the aid of the YFP lineage tracer and the cell surface markers 
podoplanin (Schacht et al., 2005) and Sca-1 (Kim et al., 2005), we 
isolated LSCC and LADC tumor cells, respectively, from CKFY mice 
by FACS. LADC and LSCC populations appeared morphologically 
distinct in culture (Fig. S4 A). Whereas LSCC cells proliferated in 
monolayers and expressed the LSCC-specific markers CK5 and 
CK14, LADC cells formed aggregates in vitro and expressed Sftpc 
and TTF1 (Fig. 3, A and B). Complete recombination of Fbxw7 
and KRasG12D was confirmed by PCR analysis of genomic DNA 
isolated from both cell types (Fig. S4 B). LSCC, but not LADC, cells 
in culture expressed a LSCC transcriptional signature similar 
to that of primary tumor cells from the KF model (Fig. S4 C). 
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Following orthotopic transplantation into immunocompromised 
mouse recipients, mice that received primary LSCC tumor cells 
developed tumors with CK5+ staining typical of LSCC within 
10 wk (Fig. 3 C). In contrast, LADC cells initiated lung tumors 
expressing the LADC-specific marker TTF1 (Fig.  3  C). Thus, 
CKFY-derived primary LADC and LSCC tumor cells retain 
Figure 2. Lung LSCC originates from CC10+ luminal cells in the KF model. (A) Immunofluorescent staining for CC10, FoxJ1, Sftpc, and GFP in CK19-CreERT; 
R26-LSL-YFP mouse lung sections at 1 wk after induction. Images representative of three animals. Bars, 20 µm. Tam, tamoxifen. (B) Ciliated FoxJ1+ cells were 
targeted by intratracheal (IT) delivery of Lenti-FoxJ1-Cre virus to KF animals. The graph shows the quantification and localization of lung tumors produced. 
n = 12 lungs. Plots indicate mean ± SD. (C) Club CC10+ cells were targeted by intratracheal delivery of Ad5-CC10-Cre virus to KF animals. The graph shows the 
quantification and localization of lung tumors produced. n = 17 lungs. Plots indicate mean ± SD. (D) Scheme for analysis of cell proliferation in CK19-CreERT; 
KRasG12D; Fbxw7f/f; R26-LSL-YFP (CKFY) mice. (E) Lung serial sections from CKFY mice were immunostained for CC10, CK5, and EdU at 3, 7, 14, 21, and 28 d 
after tamoxifen injection. Arrows indicate proliferating cells. Arrowheads indicate double CK19+CK5+ cells. Images representative of five animals. Bars, 20 µm. 
(F) Quantification of proliferating CC10+ and CK5+ cells at the indicated time points. Graph indicates mean ± SD of five animals. See also Figs. S1, S2, and S3.
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tumor-specific transcriptional signatures and marker protein 
expression and give rise to distinct tumor types.
LSCC tumors are resistant to the chemotherapeutic 
agent cisplatin
To compare the response of LADC and LSCC tumor cells to 
chemotherapy, we treated them in vitro with 10 µM cisplatin, 
equivalent to the maximal short-term plasma concentration in 
patients treated with the drug (Urien and Lokiec, 2004). LADC 
cells were highly sensitive to cisplatin, but treatment had only a 
marginal effect on LSCC cell growth (Fig. 3 D). This contrasting 
behavior of murine KF LADC and LSCC was mirrored in a panel 
of human lung tumor cell lines, with human LSCC cells showing 
resistance to cisplatin compared with LADC cells (Fig. 3 D).
We then tested the effect of the maximum tolerated dose of 
cisplatin (7 mg/kg; Oliver et al., 2010) on LADC and LSCC tumors 
in vivo, in KF mice infected with Ad5-CMV-Cre virus (Fig. 3 E). 
In vivo imaging showed reduced lung tumor mass in mice 
treated with cisplatin compared with vehicle control (Fig. 3 F). 
On histological inspection, cisplatin-treated lungs showed a 
significant reduction in LADC lesions, but lesions expressing 
the LSCC-specific marker ΔNp63 did not show any tumor 
regression (Fig. 3, G and H), supporting resistance of LSCC cells 
to chemotherapy.
LSCC tumors show increased LUB AC expression and 
linear ubiquitylation
To understand the molecular basis of the difference in cisplatin 
sensitivity between LADC and LSCC tumors, we examined mRNA 
and protein expression in KF LADC and LSCC tumor cells. The 
levels of known FBW7 substrates, including MCL1, c-Jun, NICD1 
(inferred from transcription levels of its target genes), and c-
Myc, which all have reported roles in cell survival (Davis et al., 
2014), were not significantly different in LADC versus LSCC cells 
(Fig. S4, D and E). In contrast, our transcriptome data revealed 
that HOIP (Rnf31), HOIL-1 (Rbck1), and Sharpin, components 
of LUB AC, were more highly expressed in LSCC compared with 
LADC tumor cells, which was confirmed by quantitative PCR 
(qPCR) and immunoblotting (Fig. 4, A and B). In agreement with 
these findings, analysis of TCGA data showed that amplification 
or mRNA up-regulation of the genes encoding LUB AC compo-
nents was more common in human LSCC compared with LADC 
(Fig. 4 C and Fig. S4 F). We examined the expression of LUB AC 
components in 30 primary human lung tumor samples and con-
firmed increased expression of HOIL-1 and HOIP mRNA in LSCC 
compared with LADC (Fig. 4 D).
Consistent with increased LUB AC expression, LSCC cell lysates 
showed increased Met1-linked ubiquitylation, which further 
increased following TNFα stimulation (Fig. 4 E). The increase in 
linear ubiquitylation was not due to an overall change in total 
ubiquitin species or seen with other ubiquitin chain topologies 
(Fig. 4 E). Moreover, capture of intact TNFR1 complex-I using 
FLAG-tagged TNFα and immunoblotting with Met1 linkage-
specific antibodies showed that linear ubiquitylation of 
complex-I proteins was also increased in LSCC compared with 
LADC cells (Fig. 4 F). Together, our data indicate that LSCC have 
higher levels of LUB AC and linear ubiquitylation.
LSCC tumors show increased NF-κB signaling
To determine whether the increased linear ubiquitylation seen in 
LSCC cells was associated with increased NF-κB signaling, we ex-
amined levels of the NF-κB inhibitor IκBα and Ser536 phosphory-
lation of the NF-κB subunit p65 (P-p65) in LADC and LSCC cells. 
LSCC cells had lower levels of IκBα and higher levels of P-p65 
compared with LADC cells, suggesting active NF-κB (Fig. 5 A). In 
line with this, p65 showed strong nuclear localization in LSCC but 
not in LADC tumor cells (Fig. 5 B). Correspondingly, basal expres-
sion of the NF-κB–dependent target genes TNFα and CCL2 was 
higher in LSCC than LADC cells, and was further increased by 
TNFα stimulation (Fig. 5 C). LSCC cells, both in culture and from 
primary tumors, also showed up-regulation of multiple NF-κB 
target genes compared with LADC cells (Fig. S4 G).
The differences in NF-κB activation between LADC and LSCC 
were conserved in human LADC and LSCC cell lines (Fig. 5, D and 
E), and this finding was further confirmed in a panel of primary 
human LSCC tumor samples. Protein extracts from 25 human 
LADC and 31 human LSCC freshly isolated tumor resections were 
generated, and p65 phosphorylation was analyzed (representa-
tive examples in Fig. 5 F). Quantification of P-p65/total-p65 ratio 
revealed substantially increased P-p65 levels in human LSCC, and 
expression of CCL2 and TNFα was correspondingly increased 
(Fig. 5, G and H). These data suggest that a high level of NF-κB 
activation is a feature of LSCC, both in the KF mouse model and 
human LSCC patients.
Increased NF-κB signaling in LSCC tumors mediates 
cisplatin resistance
To assess the importance of LUB AC and NF-κB activity in the 
chemotherapy resistance of LSCC, we treated primary KF LSCC 
tumor cells with gliotoxin, which inhibits LUB AC by direct bind-
ing to HOIP (Sakamoto et al., 2015), or with a TAK1 inhibitor, 
5Z-7-oxozeaenol (5Z-7), which is required for activation of IKK 
and IKK-mediated degradation of IκB (Wang et al., 2001). Both 
gliotoxin and 5Z-7 decreased NF-κB activity, as measured by 
P-p65 and expression of CCL2 and TNFα (Fig. 6, A and B). LSCC 
cells were more sensitive to gliotoxin than LADC cells, and glio-
toxin sensitized LSCC cells to cisplatin, suggesting that the che-
moresistance of LSCC tumor cells is mediated, at least in part, 
by LUB AC (Fig. 6 C). In support of this idea, knockdown of the 
LUB AC components HOIL-1 or HOIP also sensitized LSCC cells 
to cisplatin (Fig.  6, D–F). Treatment with 1  µM 5Z-7 strongly 
sensitized murine LSCC cells to cisplatin (Fig. 6 G; combination 
index [CI] 0.39, indicating synergistic activity). The combination 
of 5Z-7 and cisplatin was more effective than cisplatin alone in 
four of five human LSCC cell lines (Fig. S5 A). Cisplatin did not 
have an additional effect on inhibition of P-p65 by 5Z-7 (Fig. S5 
B). Since both human and mouse LADC cells were already sensi-
tive to cisplatin alone, the additional effect of the combination 
treatment was less striking in LADC (Fig. 6 G and Fig. S5 A). To 
confirm that the effect of 5Z-7 was via inhibition of TAK1, we 
knocked down TAK1 in LSCC cells. Like 5Z-7, siTAK1 sensitized 
LSCC cells to cisplatin, and addition of 5Z-7 did not significantly 
increase sensitivity (Fig. 6, H and I). Inhibition of the TAK1 target 
and NF-κB upstream regulator IKK also sensitized LSCC cells to 
cisplatin (Fig. S5 C).
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Figure 3. LSCC tumors are resistant to the chemotherapeutic agent cisplatin. (A) LADC and LSCC cells were isolated from CKFY mice 4 wk after tamoxifen 
injection, and CK5 and CK14 expression was analyzed by qPCR and immunostaining. n = 2 independent isolations. Bars, 20 µm. (B) Sftpc and TTF1 expression in 
CKFY LADC and LSCC cells (n = 2 independent isolations) was analyzed by qPCR and immunostaining. Bars, 20 µm. (C) Top: Scheme summarizing the protocol 
used to isolate LADC and LSCC cells from CKFY mice and to validate their tumoral properties in nude mice. Bottom: Representative IHC staining of lung tumor 
sections derived from isolated LADC and LSCC tumor cells (n = 2 independent isolations) after intratracheal (IT) injection. CKFY-derived, LSCC, and LADC tumor 
cells were identified by GFP, CK5, and TTF1, respectively. Bars, 100 µm. Tam, tamoxifen. (D) LADC, but not LSCC, cells from CKFY mice and human tumor cell 
lines are highly sensitive to cisplatin (CPPD) treatment (n = 4 independent experiments). (E) 9–11 wk after Ad5-CMV-Cre infection, KF mice were treated with 
PBS or cisplatin (7 mg/kg) and monitored for response. (F) In vivo imaging by micro-computed tomography (micro-CT) of the lungs of animals treated as in 
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LUB AC or TAK1 inhibition sensitizes LSCC tumors to cisplatin 
chemotherapy in preclinical models
Next, we investigated the effect of combining cisplatin with in-
hibition of the TAK1-LUB AC/IKK-NF-κB axis in both subcutane-
ous lung tumor grafts and autochthonous lung cancer models. 
Pilot experiments suggested that the combination of maximal 
tolerated doses of cisplatin (7 mg/kg) and 5Z-7 (15 mg/kg) or 
gliotoxin (5 mg/kg) was not well tolerated (mice experienced 
>15% weight loss), so we used half doses of both drugs in all com-
bination-treatment experiments. The combination of 3.5 mg/kg 
cisplatin and 7 mg/kg 5Z-7 strongly suppressed the growth of 
subcutaneous lung tumor grafts (Fig. 7 A). Cisplatin combined 
with 2.5 mg/kg gliotoxin had a similar effect (Fig. 7 A).
To validate the therapeutic efficacy of the combination 
therapy in a preclinical lung tumor model, we used KF mice 
infected with Ad5-CMV-Cre virus (Fig. 7 B). 9 wk after infection, 
when mice had developed lung tumors, we started treatment. As 
observed with the 7 mg/kg cisplatin dose (Fig. 3 H), treatment 
with 3.5 mg/kg cisplatin alone reduced exclusively LADC 
tumors, with LSCC tumors being nonresponsive (Fig.  7  C). 
However, combination treatment with 5Z-7 sensitized LSCC 
tumors to cisplatin and induced a significant reduction in LSCC 
tumor number (Fig. 7, C and D). IHC analysis of Ki67 and active 
caspase-3 in tumors treated with cisplatin plus 5Z-7 showed 
decreased cell proliferation and increased cell death compared 
with vehicle-treated tumors (Fig. S5, D and E). TAK1 inhibition 
also increased cisplatin efficacy toward LADC tumors (Fig. 7, C 
and D), albeit incrementally.
Using the same experimental setup, we also tested the combi-
nation of gliotoxin plus cisplatin in tumor-bearing KF mice. Al-
though neither gliotoxin nor cisplatin had a significant effect on 
LSCC tumor burden alone, the combination treatment reduced 
LSCC tumor number by >80% (Fig. 7 E). The remaining tumors 
also showed strongly reduced Ki67 positivity (Fig. S5 D). Inter-
estingly, unlike 5Z-7, addition of gliotoxin did not significantly 
increase cisplatin sensitivity in LADC tumors, making the combi-
nation treatment effect with gliotoxin specific to LSCC (Fig. 7 E).
This experimental setting also allowed us to monitor 
potential side effects that could result from the combination 
treatments. Animals tolerated the drug combinations well, with 
no significant loss of body weight (Fig. S5 F). Importantly, given 
the risk of renal toxicity with cisplatin chemotherapy (Sahni et 
al., 2009), we found no evidence of morphological changes or 
fibrosis in the kidneys of combination therapy–treated versus 
vehicle-treated animals (Fig. S5 G). Immune infiltration of CD4+ 
T cells and macrophages, which plays a role in the development of 
cisplatin-induced kidney injury, was not significantly different 
between the treatment groups, and there was no evidence of cell 
death in the kidney (Fig. S5 H). Thus, combination therapy with 
3.5 mg/kg cisplatin and 7 mg/kg 5Z-7 or 2.5 mg/kg gliotoxin is 
well tolerated by adult mice.
To interrogate the therapeutic effect of combination treat-
ment in advanced lung cancer, we treated KF mice with a very 
high lung tumor load (Fig. 8 A). Vehicle- and cisplatin-treated 
KF mice all had to be sacrificed within 1–2 wk of treatment onset 
(median survival of 7 and 12 d, respectively). The combination of 
cisplatin and 5Z-7 treatment resulted in a significant increase in 
survival, with five of six animals surviving for >7 wk (Fig. 8 B). 
Because gliotoxin/cisplatin combination therapy was more effec-
tive on LSCC than LADC tumors (Fig. 7 E), we did not test this 
combination in late-stage KF mice, since both tumor types would 
need to be controlled to achieve survival benefit. Nevertheless, 
this experiment suggests that 5Z-7/cisplatin combination ther-
apy could be of therapeutic benefit for lung cancer patients with 
advanced disease.
Overall, these data identify LUB AC levels, and NF-κB activity, 
as a determinant of chemotherapy resistance in squamous lung 
tumors and suggest LUB AC or TAK1 inhibitors in combination 
with platinum-based drugs as a possible therapy for LSCC.
Discussion
Here, we show that inactivation of Fbxw7 concomitant with 
KRasG12D expression in the adult mouse lung (KF model) leads to 
both LSCC and LADC formation. Using lung cell type–restricted 
Cre viruses, we showed that KF LADC tumors originate mainly 
from alveolar Sftpc+ cells, but that targeted inactivation of 
Fbxw7 and activation of KRasG12D in club CC10+ cells generated 
predominantly LSCC lesions. In contrast, basal cells did not 
give rise to LSCC tumors in this mouse model. As observed in 
human patients, KF LSCC tumors were located in, and adjacent 
to, the airways and expressed biomarkers characteristic of 
human LSCC, such as CK5 and ΔNp63. During LSCC progression, 
lesions lost CC10 and gained CK5 expression. Given FBW7’s 
role in regulating cell differentiation, it is possible that Fbxw7 
inactivation (in our KF model) or loss of FBW7 protein (in human 
LSCC) causes some CC10+ cells to lose their identity and acquire 
a squamous phenotype.
Activation of KRasG12D, with or without concomitant p53 inacti-
vation (KP model), induces LADC in both CC10+ and Sftpc+ popula-
tions, with the tumors being located predominantly in the alveolar 
space (Sutherland et al., 2014). We made similar observations re-
garding LADC development in the KF model. Sftpc+ cells and CC10+ 
cells generated LADC lesions; however, in addition CC10+ cells 
efficiently originated LSCC. Sutherland et al. (2014) reported that 
although KRasG12D was activated in many CC10+ cells that line the 
bronchi and bronchioles, they rarely observed tumor formation 
in this area. Thus, CC10+ cells located near the airways appear to 
be susceptible to the KF, but not to the KP oncogene combination.
The cell of origin of LSCC has been recently studied in several 
mouse models, with different results. Depending on the nature 
of the driver mutations, either basal, club, or alveolar type II cells 
E after 4–5 wk of treatment. Images representative of two animals. H, heart; dotted line, tumor mass. (G) Lung histology of animals treated as in E, showing 
both LADC (TTF1+) and LSCC (ΔNp63+) tumors in mice receiving vehicle but only LSCC in mice receiving cisplatin. Images representative of two animals. 
(H) Quantification of LADC and LSCC tumors per animal in control and cisplatin-treated mice. n = 2 animals per condition. Plots indicate mean and range; 
Student’s one-tailed t test was used to calculate P values (*, P = 0.0305). See also Fig. S4.
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had the capability to give rise to LSCC (Xu et al., 2014; Ferone et 
al., 2016; Jeong et al., 2017). These findings suggest that different 
cell types can be lung LSCC-initiating cells when supplied with 
the right set of oncogenic triggers.
Unlike LADC, there are few approved targeted therapies 
against LSCC. Consequently, despite its limited effectiveness on 
disease progression and prognosis, patients with LSCC receive 
the same conventional platinum-based chemotherapy today 
as they would have received two decades ago (Scagliotti et al., 
2008; Liao et al., 2012; Gandara et al., 2015; Fennell et al., 2016; 
Isaka et al., 2017).
We identified increased LUB AC expression and linear ubiqui-
tylation in LSCC tumors, correlating with activation of NF-κB sig-
naling in human and mouse LSCC. Notably, all five human LSCC 
cell lines tested showed increased p65 phosphorylation and were 
resistant to cisplatin (Fig. 5 D and Fig. 3 D), despite the fact that 
in at least three of these cell lines, FBXW7 is not mutated (Forbes 
et al., 2017). Moreover, the same KF driver oncogene combination 
Figure 4. LUB AC expression and linear ubiquitylation are increased in LSCC compared with LADC cells. (A) Relative mRNA expression of LUB AC com-
ponents in LSCC and LADC murine cells from KF mice, measured by real-time PCR. Student’s two-tailed t test was used to calculate P values (***, P ≤ 0.0001). 
Graph shows mean + SD of six experiments. (B) Immunoblots showing the abundance of the three LUB AC components HOIP (RNF31), HOIL-1, and Sharpin, 
in LADC and LSCC cells from the KF mouse model. Blots representative of four independent experiments. MW, molecular weight. (C) TCGA data from http:// 
www .cbioportal .org showing frequency of alterations in genes encoding LUB AC components in human LSCC and LADC. n = 230 LADC, 179 LSCC samples. 
(D) Relative mRNA expression of LUB AC components in LSCC (n = 19) and LADC (n = 11) patient samples from the Cordoba Biobank, measured by real-time 
PCR. The P value was calculated using the Student’s t test (*, P = 0.036; **, P = 0.0029). Plots indicate mean ± SEM. (E) Immunoblots of different polyubiquitin 
chains in whole-cell lysates from untreated (no exogenous stimulation) or TNFα-stimulated LADC and LSCC cells from KF mice. (F) TNFR1 complex I immuno-
precipitated (IP) from KF LADC and LSCC cells using Flag-tagged TNFα under nondenaturing conditions and immunoblotted with Met1-Ub–specific antibodies. 
Blots representative of two independent experiments. WB, Western blot. See also Fig. S4.
Ruiz et al. 
LUB AC determines chemoresistance in squamous lung cancer
Journal of Experimental Medicine
https://doi.org/10.1084/jem.20180742
459
which resulted in cisplatin-resistant LSCC failed to induce cispla-
tin resistance in LADC cells. Therefore, high NF-κB activity, and 
consequently cisplatin resistance, is unlikely to be a direct mo-
lecular consequence of the absence of FBW7, but rather a general 
property of LSCC tumor cells.
Both murine and human LSCC tumor cells were resistant to 
cisplatin, and inhibition of NF-κB signaling using either gliotoxin 
or 5Z-7-oxozeaenol resulted in sensitization of LSCC tumor cells 
to cisplatin chemotherapy, suggesting a crucial role of increased 
NF-κB signaling in the chemotherapy response of LSCC. Impor-
tantly, our results show that using a half dose of cisplatin in combi-
nation with gliotoxin or 5Z-7-oxozeaenol is sufficient to decrease 
proliferation and impair LSCC tumor growth. As a consequence, 
tumor-bearing mice survived significantly longer than control 
and cisplatin-treated animals. It is important to note that mice 
did not show significant weight loss or renal toxicity. Thus, our 
combination strategy provides significant therapeutic benefit.
In summary, our study demonstrates that the TAK1-LUB AC/
IKK-NF-κB axis is a key mediator of LSCC progression and hence 
represents a suitable therapeutic target. Therefore, LUB AC or 
NF-κB inhibition combined with conventional chemotherapy 
should be considered as a potential therapy for human LSCC.
Figure 5. Mouse and human LSCC tumors show activated NF-κB signaling. (A) Western blots showing LSCC cells from KF mice have a higher baseline level 
of phospho-p65 and a lower level of IκBα. Blots representative of two independent experiments. MW, molecular weight. (B) Immunofluorescent staining on 
LADC and LSCC primary tumor cells (top, representative of n = 3 independent isolations) and IHC staining of LADC and LSCC tumors (bottom, representative of 
n = 3 animals) from KF mice showing increased nuclear localization of p65 in LSCC. (C) LSCC cells have a higher baseline level of NF-κB–dependent target gene 
(CCL2 and TNFα) expression and respond more following TNFα stimulation when compared with LADC cells. Relative mRNA levels were measured by real-time 
PCR following TNFα stimulation (10 ng/ml) of LADC and LSCC cells for the indicated times. Graph represents mean (+ SD) of three independent experiments 
performed in duplicate. (D) Western blots showing that human LSCC tumor cell lines exhibit higher levels of p65 activation compared with LADC cell lines. 
Ratio of phospho-p65 to total p65 normalized to GAP DH is given below. Samples were run in parallel, and identical exposures were used. (E) Quantification 
of results in D. Student’s one-tailed t test was used to calculate P values (**, P = 0.0095). Plots indicate mean ± SEM. (F) Human LSCC tumors exhibit higher 
levels of p65 activation compared with LADC samples. Ratio of phospho-p65 to total p65 normalized to actin is given below. Samples were run in parallel, and 
identical exposures were used. (G) Quantification of results in F and from a total of 25 LADC and 31 LSCC patient tumors. Student’s two-tailed t test was used 
to calculate P values (***, P = 0.0002). Plots indicate mean ± SEM. (H) Relative mRNA expression of CCL2 and TNFα in LSCC (n = 19) and LADC (n = 11) patient 
samples from the Cordoba Biobank, measured by real-time PCR. Student’s two-tailed t test was used to calculate P values (*, P = 0.01; **, P = 0.0049). Plots 
indicate mean ± SEM. See also Fig. S4.
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Figure 6. Inhibition of LUB AC or TAK1 sensitizes LSCC cells to cisplatin. (A) Both 5Z-7 and gliotoxin inhibit NF-κB signaling, as measured by 
phospho-p65 (Ser536). Blots represent two independent experiments. MW, molecular weight. (B) Expression of NF-κB–dependent target genes (CCL2 
and TNFα) in murine LSCC cells is decreased in the presence of the TAK1 inhibitor 5Z-7 or the LUB AC inhibitor gliotoxin. Relative mRNA levels measured 
by real-time PCR. Data are mean + SD of three independent experiments performed in triplicate. (C) LSCC cells are highly sensitive to gliotoxin treatment, 
and gliotoxin sensitizes cells to cisplatin. Data are mean + SD of two independent experiments performed in duplicate. ***, P < 0.0001 versus vehicle, 
two-way ANO VA. (D) siRNA-mediated knockdown of the LUB AC components HOIP and HOIL-1 decreases LSCC cell resistance to cisplatin. Graph 
shows mean + SD of three independent experiments performed in triplicate. ***, P < 0.0001 versus vehicle, one-way ANO VA. (E) Validation of HOIL-1 
knockdown in LSCC cells using two independent siRNAs. Graphs represent mean + SEM of three independent experiments. (F) Validation of HOIP 
knockdown in LSCC cells using three independent siRNAs. Graphs represent mean + SEM of three independent experiments. (G) In vitro LSCC and 
LADC cells are highly sensitive to cisplatin (CPPD) and 5Z-7-oxozeaenol combination treatment. Data are mean + SD of two independent experiments 
performed in duplicate. ***, P < 0.0001 versus vehicle, two-way ANO VA. (H) Validation of TAK1 knockdown in LSCC cells using three independent 
siRNAs. Graphs represent mean + SEM of three independent experiments. (I) siTAK1 LSCC cells are sensitive to cisplatin (CPPD), and addition of 5Z-7 
does not affect CPPD sensitivity in the presence of TAK1 knockdown. P values calculated using one-way ANO VA test. Graph shows mean + SD of two 
independent experiments performed in quadruplicate. ***, P < 0.0001 versus vehicle, one-way ANO VA. See also Fig. S5.
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Figure 7. Combination treatment with cisplatin and TAK1 inhibitor or gliotoxin sensitizes LSCC tumors. (A) In vivo tumor graft growth curves of LADC 
and LSCC cells subcutaneously injected in both flanks of athymic NU/NU mice. Mice with palpable tumors were treated with i.p. injections as follows. Top: Cis-
platin (CPPD; n = 3), 5Z-7-oxozeaenol (n = 3), 5Z-7-oxozeaenol+cisplatin (n = 3), or vehicle (n = 3). Bottom: Cisplatin (n = 3), gliotoxin+cisplatin (n = 4), or vehicle 
(n = 4). Data are mean ± SEM of the tumor volumes. P values calculated from two-way ANO VA. *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001 versus 
vehicle. (B) Scheme depicting experimental design for in vivo test of cisplatin (3.5 mg/kg) alone or in combination with 5Z-7-oxozeaenol (7 mg/kg) or gliotoxin 
(2.5 mg/kg). (C) Quantification of LADC and LSCC tumors per animal in control, cisplatin-treated, and 5Z-7 combination-treated KF mice. P values calculated 
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Materials and methods
Analysis of TCGA data
Data from TCGA Research Network (TCGA Lung Adenocarcinoma 
and Lung Squamous Cell Carcinoma Provisional complete sample 
sets), including mutations, putative copy-number alterations, 
and mRNA z-scores (RNA Seq V2 RSEM; threshold 2.0), were 
analyzed using cBioportal software (Cerami et al., 2012) and 
visualized using the standard Oncoprint output.
Human lung tumor analysis
Human biological samples used in the current study were col-
lected, stored, and managed by the Cordoba node belonging to 
the Biobank of the Andalusian Health Service (Servicio Andaluz 
de Salud-SAS) and approved by the Ethics and Clinical Research 
Committee of the University Hospital Reina Sofia. All subjects 
gave informed consent. Pathologists assessed all samples be-
fore use. Human lung samples were stained for FBW7 expres-
sion, and protein lysates were analyzed for phospho-p65, p65, 
and actin by Western blotting. mRNA extracted from the sam-
ples was analyzed by qPCR. Primers and antibodies are listed in 
Tables S1 and S3.
Mouse strains
The KRasG12D (Jackson et al., 2001), R26-LSL-YFP (Srinivas et al., 
2001), CK5-CreERT (Indra et al., 1999), CK14-CreERT (Vasioukhin et 
al., 1999), CK19-CreERT (Means et al., 2008), and Fbxw7f/f (Jandke 
et al., 2011) mouse lines have been previously described. All an-
imal experiments were approved by the Francis Crick Institute 
Animal Ethics Committee and conformed to UK Home Office 
regulations under the Animals (Scientific Procedures) Act 1986 
including Amendment Regulations 2012.
Genetic labeling experiments
For all experiments, adult (6–9 wk) age- and strain-matched 
animals were used. Mice were injected i.p. with 100 µg/kg body 
weight of tamoxifen dissolved in peanut oil for a consecutive 2–5 
d. Analyses were performed at different time points after injec-
tion. Where indicated, EdU (50 mg/kg) was given i.p. 10 h before 
the end of the experiment.
Generation of recombinant cell type–specific Cre viruses
Human FoxJ1 promoter-Cre and bovine cytokeratin 5 promoter-
Cre constructs have been previously described (Ramirez et al., 
2004; Zhang et al., 2007) and were subcloned either in LV-PL1 
as SpeI–BsrGI or in pAd5mcspA as NotI–NotI, respectively. 
Ad5-CC10-Cre, Ad5-CMV-Cre, and Ad5-SPC-Cre have been 
previously described (Sutherland et al., 2011). High-titer viruses 
were amplified and purified for use in vivo by the University 
of Iowa Gene Transfer Vector Core, supported in part by the 
National Institutes of Health and the Roy J. Carver Foundation, 
for viral vector preparation.
Intratracheal Adeno-Cre or Lenti-Cre virus administration
6–8-wk-old mice were intratracheally intubated with 50 µl of 
purified Cre viruses: Ad5-CMV-Cre, Ad5-SPC-Cre, Ad5-CC10-
Cre, and Ad5-CK5-Cre were used at 2.5 × 107 PFU; Lenti-FoxJ1-Cre 
was used at 1.4 × 108 PFU. To target basal CK5+ cells, mice were 
administered naphthalene (250 mg/kg) 3 d before Ad5-CK5-Cre 
infection. Ad5-CK5-Cre–calcium phosphate coprecipitates were 
prepared according to published methods (DuPage et al., 2009).
Histology, IHC, and immunofluorescence
For histological analysis, lungs were fixed overnight in 10% neutral 
buffered formalin. Fixed tissues were subsequently dehydrated 
and embedded in paraffin, and sections (4 µm) were prepared 
for H&E staining, IHC, or immunofluorescence. Antibodies are 
given in Table S3. To quantify EdU+ cells (stained using Click-iT 
EdU Alexa Fluor 647 Imaging kit; C10340; Thermo Fisher 
Scientific), 25 airways were scored from at least three mice. For 
quantification of Ki67, C3A, CD4, and F4/80, 15–30 representative 
sections were analyzed with MetaMorph 6.1 or ImageJ-IHC tool 
box software. Data are represented as mean ± SEM.
Isolation of tumor cells by FACS
Single lung cell suspensions were obtained by 20-min digestion in 
a mix of collagenase (0.5–3 mg/ml; Worthington) and Dispase (1 
mg/ml; Invitrogen), followed by filtration through cell strainers 
(100, 70, and 40 µm; Ruiz et al., 2014). Cells from CKFY mice were 
first sorted for GFP expression and then sorted for Sca1 (LADC 
cells) or podoplanin (LSCC cells), using antibodies listed in Table 
S3. The isolated cells were cultured in N2B27 medium containing 
EGF (10 ng/ml; Pepro Tech) and FGF2 (20 ng/ml; Pepro Tech).
RNASeq/gene expression profile analysis
LSCC and LADC cells were isolated as explained above. RNA 
was isolated using the MagMAX-96 total RNA Isolation 
Kit, following the manufacturer’s instructions (Thermo 
Fisher Scientific). Read mapping and abundance estimation 
were performed using RSEM v1.2.31 (Li and Dewey, 2011) 
running STAR v2.5 (Dobin and Gingeras, 2015) against the 
Mus musculus Ensembl 86 transcriptome (GRCm38), with 
the following nondefault command line arguments: “–star–
forward-prob 0.” Further analysis was conducted using R 
v3.4.0 running Bioconductor v3.5. Gene-level read count 
estimates were rounded to integer values and used by DESeq2 
(Love et al., 2014) to assess differential expression between 
LSCC and LADC replicate groups using the “DESeq2” function 
with default settings.
Normalized counts were used to construct an expression 
heatmap for LSCC signature genes common to two previous 
studies (Xu et al., 2014; Ferone et al., 2016). For the purposes 
of visualization, gene counts across samples were converted to 
z-scores and ordered by magnitude of change. 
using two-way ANO VA (n = 6 vehicle and cisplatin, n = 8 combination). **, P = 0.009; ***, P < 0.001. Plots show mean ± SEM. (D) Histological analysis of LADC 
and LSCC tumors in control, cisplatin-treated, and combination-treated animals. Representative of animals in C (vehicle, cisplatin, and 5Z-7 combination) and 
E (gliotoxin combination). Bars, 50 µm. (E) Quantification of LADC and LSCC tumors per animal in control, cisplatin-treated, and gliotoxin combination–treated 
KF mice. P values calculated using two-way ANO VA (n = 3 each treatment; *, P = 0.031; **, P = 0.0013). Plots show mean ± SEM. See also Fig. S5.
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RNASeq data were deposited in the Gene Expression Omnibus 
(GEO) repository under accession no. GSE123716.
DNA isolation and allele recombination PCR
To verify Cre-mediated recombination of KRasG12D and Fbxw7 
alleles, genomic DNA from cells was isolated by digestion in 
DirectPCR Lysis Reagent (Viagen Biotech). PCR primers used to 
detect the efficiency of recombination of Fbxw7 and KRasG12D 
alleles are given in Table S2.
Gene expression analysis
RNA was isolated from sorted cells using an RNeasy Micro Kit 
(Qiagen), and cDNA amplification was performed using the 
Transcriptor First Strand cDNA Synthesis Kit (Roche). Diluted 
cDNAs were used for quantitative real-time PCR SYBR-Green de-
tection of target genes, using primer sequences given in Table S1.
Immunoblot analysis
Cells were lysed in ice-cold lysis buffer (20 mM Tris HCl, pH 7.5, 
5 mM MgCl2, 50 mM NaF, 10 mM EDTA, 0.5 M NaCl, and 1% Tri-
ton X-100) that was completed with protease, phosphatase, and 
kinase inhibitors. Antibodies are given in Table S3.
Cell proliferation assay
Murine and human tumor cell lines were seeded at 2 × 103 and 4 
× 103, respectively, in 96-well plates and, 16 h later, were treated 
with vehicle, cisplatin (10 µM), 5Z-7-oxozeaenol (1 µM), or the 
combination. Cell confluence was measured over several days, 
using an incubator microscope system for live cell imaging (In-
cuCyte), and used as the readout for cell proliferation. Alterna-
tively, after 5 d, the cells were trypsinized and counted using 
a hemocytometer.
In vivo pharmacology with subcutaneous graft tumors
Murine LADC and LSCC tumor cells were resuspended as sin-
gle-cell suspensions at 107 cells/ml in PBS: Matrigel. 100 µl (106 
cells total) of this suspension was injected into opposite left 
(LADC) and right (LSCC) flanks of athymic NU/NU nude mice. 
Two weeks later when tumors were palpable, treatment with 
gliotoxin (2 mg/kg), cisplatin (3.5 mg/kg), and 5Z-7-oxozeae-
nol (7 mg/kg) was initiated. Mice were treated every 5 d for a 
total of four doses. Tumor grafts were measured with digital cal-
ipers, and tumor volumes were determined with the following 
formula: (length × width2) × (π/6). Tumor volumes are plotted 
as means ± SEM.
Cisplatin and 5Z-7-oxozeaenol treatment
9–11 weeks after Ad5-CMV-Cre infection, LSL-KRasG12D; Fbxw7f/f 
mice were treated with vehicle, cisplatin alone (3.5 or 7 mg/kg), 
or the combination of cisplatin (3.5 mg/kg) and 5Z-7-oxozeaenol 
(7 mg/kg) or gliotoxin (2.5 mg/kg) once a wk for 2 wk, followed 
by a 1-wk break, and this regimen was repeated for a total of four 
doses before histological analysis or until humane survival end-
point was reached.
HOIL, HOIP, and TAK1 genetic silencing
LSCC cells were transfected with specific siRNAs against the 
HOIL/Rbck1, HOIP/Rnf31, and TAK1/Map3k7 genes (sequences 
in Table S2), using Lipofectamine RNAiMAX and 25 nM of each 
siRNA according to the manufacturer’s instructions (Dharmacon). 
96 h later, cells were treated with cisplatin (10 µM) or 5Z-7 (1 µM), 
and after 3–4 d, cell viability was measured as the intracellular 
ATP content using the CellTiter-Glo Luminescent Cell Viability 
Assay (Promega), following the manufacturer’s instructions.
CI assays
For drug combination experiments, LSCC cells were seeded in 
96-well plates at a density of 2 × 103 cells per well, and TAK1 in-
hibitor+cisplatin combination was added for 3–4 d, using DMSO 
as a control. Cell viability was measured as explained above. The 
CI was calculated using CalcuSyn software (Biosoft) following the 
method of Chou and Talalay (1983).
TNF-α treatment
2 × 105 LADC and LSCC cells were seeded in 12-well plates, and 
24 h later they were treated with human recombinant TNF (10 
ng/ml) for 2, 4, and 6 h.
TNFR1 complex I immunoprecipitation
Cells were seeded in 15-cm dishes and treated as indicated with 3x 
FLAG-hTNF (5 mg/ml). To terminate stimulation, medium was re-
moved, and plates were washed with 50 ml of ice-cold PBS. Plates 
were frozen at −80°C until all time points were acquired. Plates 
were thawed on ice, and cells were lysed in 1% Triton X-100 lysis 
buffer (30 mM Tris-HCl, pH 7.4, 120 mM NaCl, 2 mM EDTA, 2 mM 
KCl, 10% glycerol, and 1% Triton X-100, supplemented with prote-
ase inhibitors and PR619 [10 µM]). Cell lysates were rotated at 4°C 
for 20 min then clarified at 4°C at 14,000 rpm for 30 min. Proteins 
were immunoprecipitated from cleared protein lysates with 20 ml 
of anti-FLAG M2 beads (Sigma) with rotation overnight at 4°C. For 
the 0-h sample, 5 mg/ml of FLAG-TNF was added after lysis. Sam-
Figure 8. Combination treatment with 
cisplatin and TAK1 inhibitor increases survival 
even with advanced tumors. (A) Scheme 
depicting experimental design for end-stage 
survival analysis of control, cisplatin-treated, and 
combination-treated KF mice. IT, intratracheal. 
(B) Kaplan-Meier curve showing effect of 
cisplatin (CPPD; 3.5 mg/kg) or cisplatin plus 
5Z-7-oxozeaenol (7 mg/kg) treatment on survival 
of tumor-bearing KF mice (n = 4 vehicle and 
cisplatin, n = 6 combination). P value calculated 
using log-rank (Mantel–Cox) test (**, P = 0.0011). 
See also Fig. S5.
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ples were washed four times in 1% Triton X-100 buffer with PR619 
(10 µM) and eluted by boiling in 60 ml 1× SDS loading dye.
Statistics
Statistical analysis was performed using GraphPad Prism soft-
ware. Student’s t tests and one-way or two-way ANO VA were 
used to generate P values, as indicated in the figure legends. For 
Fig. 8 B, a log-rank (Mantel–Cox) test was used. A P value <0.05 
was considered significant.
Online supplemental material
Fig. S1 shows gene alteration data from TCGA, additional IHC of 
KF tumor samples, and IHC data from the Ad5-CK5-Cre model. 
Fig. S2 shows data from the CK19-Cre model. Fig. S3 shows IHC 
data from the lung tumor models in Fig. 2. Fig. S4 shows validation 
of LADC and LSCC cells isolated from CKFY mice, comparison of 
Fbw7 substrates in LADC and LSCC cells, and increase in LUB AC 
alterations and NF-κB target gene expression in human and mu-
rine LSCC, respectively. Fig. S5 shows the effect of combination 
treatment on human lung tumor cell lines, IHC quantifications 
from combination-treated animals, and toxicity assessments for 
the combination treatment. Tables S1 and S2 show primers and 
siRNA target sequences. Table S3 shows antibodies.
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